Citigroup’s TG Therapeutics TGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$997K Buy
+30,000
New +$894K ﹤0.01% 3119
2024
Q3
Sell
-74,900
Closed -$1.33M 5801
2024
Q2
$1.33M Buy
74,900
+35,000
+88% +$558K ﹤0.01% 2683
2024
Q1
$607K Sell
39,900
-5,000
-11% -$79.7K ﹤0.01% 3435
2023
Q4
$767K Buy
44,900
+14,600
+48% +$170K ﹤0.01% 3067
2023
Q3
$253K Sell
30,300
-13,500
-31% -$188K ﹤0.01% 3538
2023
Q2
$1.09M Buy
+43,800
New +$1.13M ﹤0.01% 2785
2023
Q1
Sell
-59,800
Closed -$707K 5854
2022
Q4
$707K Buy
+59,800
New +$434K ﹤0.01% 2920
2022
Q1
Sell
-300,000
Closed -$5.7M 6599
2021
Q4
$5.7M Buy
+300,000
New +$7.79M ﹤0.01% 1730
2021
Q1
Sell
-18,600
Closed -$968K 7340
2020
Q4
$968K Hold
18,600
﹤0.01% 3571
2020
Q3
$498K Hold
18,600
﹤0.01% 3847
2020
Q2
$362K Sell
18,600
-800
-4% -$12.9K ﹤0.01% 4549
2020
Q1
$191K Buy
19,400
+200
+1% +$2.53K ﹤0.01% 4779
2019
Q4
$213K Sell
19,200
-6,300
-25% -$47.9K ﹤0.01% 5129
2019
Q3
$143K Buy
25,500
+2,700
+12% +$18.8K ﹤0.01% 5419
2019
Q2
$197K Buy
22,800
+11,300
+98% +$85.4K ﹤0.01% 5291
2019
Q1
$92K Buy
11,500
+900
+8% +$4.86K ﹤0.01% 5828
2018
Q4
$43K Sell
10,600
-8,700
-45% -$43.2K ﹤0.01% 6360
2018
Q3
$108K Buy
+19,300
New +$221K ﹤0.01% 5827

Other funds holding TGTX

Citigroup's TGTX Position: Q1 2026 in Review

Citigroup reduced its TG Therapeutics (TGTX) stake by 27% in Q1 2026, selling an estimated $3.86M and leaving 353,979 shares worth $11.8M. The position accounts for 0.01% of the portfolio, ranked #1373.

Citigroup first reported a position in TGTX in Q2 2013 and has held it in 51 quarters since. The position peaked at $27M in Q3 2025. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Citigroup held 353,979 shares of TG Therapeutics worth $11.8M as of Q1 2026.
  • Citigroup sold 129,546 TG Therapeutics shares in Q1 2026, an estimated $3.86M.
  • TG Therapeutics made up 0.01% of Citigroup's portfolio in Q1 2026, its #1373 holding.
  • Citigroup first reported a position in TG Therapeutics in Q2 2013 and has held it in 51 quarters since.
  • Citigroup's TG Therapeutics position peaked at $27M in Q3 2025.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.